Anagenics to acquire Bio-First skincare brand for $50k in AN1 shares
Anagenics Limited (ASX: AN1) has entered into a binding agreement to acquire Bio-First, an established Australian natural skin-health brand, from Bio deNovo Group Pty Ltd. The consideration is $50k, satisfied through the issue of 8,333,333 AN1 shares at $0.006 per share.
Because the consideration is entirely in AN1 shares, cash is preserved for a relaunch of the brand. The acquisition will complete upon the issuance of shares, expected to occur during November.
Sandy Beard, Chair of Anagenics
“Bio-First is a highly complementary brand with proven formulations and a substantial existing customer base. For a modest upfront investment, we see an attractive opportunity to relaunch the brand through BLC’s existing channels and deliver a meaningful return on investment.”
When big ASX news breaks, our subscribers know first
What Anagenics acquires with Bio-First
The acquisition includes:
- The Bio-First brand IP, formulations, customer database and digital assets
- A pipeline of more than 10 developed product concepts
The customer base comprises:
- Over 17k purchasers
- A 25k+ customer email database
- 1.7k+ reviews
Bio-First complements Anagenics’ existing brands and BLC Cosmetics’ distribution activities.
Relaunch plan through BLC Cosmetics’ channels
Bio-First will be sold through BLC’s existing ecommerce, warehousing and professional beauty distribution channels. The relaunch will initially focus on:
- Reactivating existing customers
- Relaunching core products
- Expanding distribution through BLC’s clinic, salon and spa network
The deal advances Anagenics’ strategy to build value from owned brands and intellectual property. It follows the company’s announcement on 5 November 2026 of the sale of its licensing agreement, which the company said significantly strengthens the balance sheet and underpins annual royalties.
The haircare IP sale to York St Brands brings in $2.5 million in cash plus sales-linked payments of at least $350,000 a year for up to eight years, capped at $7 million, and follows the company’s first full-year profit.
What happens next for Anagenics
- Share issuance and completion of the acquisition: expected during November 2026.
- Further details of the brand portfolio review and refocusing, including the strategy to enhance scale and profitability and the evaluation of complementary investment opportunities: expected in the new year.
Want Alerts Like This on the Biotech and Health Stocks You Follow?
StockWire X Market Intelligence scores every announcement in our coverage for how significant it’s likely to be for investors, and which way it points, then alerts you on the stocks you follow. The first 1,000 founding members lock in 50% off for life: A$247 a year instead of the standard A$495. Join the founding waitlist today.